Name: ASCO® 2024 Insights: &quot;Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients&quot;
Uploaded: 2024-06-21T10:08:01.844552+00:00
Duration: 11 min 26 s
Description: ASCO® 2024 Insights: &quot;Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients&quot;

UCI Health

UCI Health is home to a devoted team of internationally-recognized physicians, researchers, educators, and students united by a single calling - to improving the lives of the people in our community and beyond.

Here, you will find discussions and presentations on cutting-edge research, clinical advancements, and physician-centric resources.

Please be advised that the content on this platform is produced specifically for physicians.
Learn more and refer a patient at https://clinicalconnection.ucihealth.org/.